Donald Engelman

Donald M. Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences,[1] a fellow of the National Institutes of Health, and has been a Guggenheim fellow.[2] He is a director of the Stryker Corporation.[3] He is involved in the creation of new cancer drugs and treatments.[4] For example, Engelman is involved in research to use peptides to aid in destroying tumors.[5]

Administration, Advising, and Consulting

Engelman has served as Director of Biological Sciences at Yale, an advisor to the Brookhaven National Laboratory, and a consultant to the Los Alamos National Laboratory.[6] He also served as Acting Dean of Yale College in 1991.[7]

Education

Engelman is a graduate (and trustee[8]) of Reed College and Yale University.[9]

Engelman Lab

Engelman directs the Engelman Laboratory at Yale.[10]

Patents

Engelman holds six United States patents for his discoveries.[11]

References

This article is issued from Wikipedia - version of the Tuesday, January 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.